EUVIMEDOdkrijte EUVIMED
CrossrefInformačná karta

The first reported use of red blood cell exchange to treat hemoglobin Evans with secondary methemoglobinemia

Lance A. Williams, Jill Adamski, Theresa N. Kinard, Natalie M. Ertz‐Archambault, Qun Lu, Kristin Gray, Jennifer L. Herrick, Leon Su, Leslie Padrnos

Journal of Clinical Apheresis · 2023-12 · 38 (6) · 755-759

DOI: 10.1002/jca.22086 ↗
AbstraktBibliografické údaje

Abstrakt

Abstract This manuscript describes a novel approach for treating patients with long‐term sequelae from hemoglobin Evans (Hb Evans). After instituting conservative therapies for approximately 2 years, our patient's symptoms continually worsened. Therefore, we performed red blood cell exchange (RBCx) to reduce his Hb Evans percentage and his co‐existing elevation of methemoglobin. Our assumptions of clinical benefit were based on our collective experience performing RBCx for patients with sickle cell disease. After the first exchange, pre‐ and post‐laboratory results supported our approach and the patient experienced marked improvement in his clinical signs and symptoms. This report provides preliminary proof of principle for the use of RBCx to treat Hb Evans and other non‐Hb S hemoglobinopathies.

Vedomosti, ktoré zodpovedajú vašej práci.

Od bezplatného začiatku cez osobnú rešerš literatúry až po kompletný Research Suite.

Zobraziť tarify →

Sú zahrnuté všetky plné texty vydavateľov?

Nie. Bibliografické záznamy, abstrakty a plné texty sú odlišné typy obsahu. To, či je plný text dostupný, závisí od zdroja, Open Access a vašich existujúcich licencií. Tarif EUVIMED nenahrádza dodatočné práva vydavateľa.

Zobraziť tarify →